• Firm commitments to raise A$70 million via placement
• Proceeds to accelerate growth strategy, including commercial expansion and R&D
• Company well-positioned for continued growth and operational success

Imricor Medical Systems, Inc. (ASX: IMR) has received firm commitments to raise A$70.0 million (US$44.1 million) via a placement to new and existing institutional and sophisticated investors. The placement was completed at an offer price of A$1.41 per CHESS Depositary Interest (CDI), representing a nil discount to the company's last traded price. The proceeds from the placement will be used to accelerate Imricor's growth strategy, including expanding commercial operations, advancing research and development, and supporting regulatory efforts. Following the raise, the company expects to have cash reserves of approximately A$87.3 million (US$55.0 million). Imricor's Chair and CEO, Steve Wedan, commented that 2025 is a year full of meaningful catalysts and groundbreaking milestones, and the strengthened balance sheet will enable the company to not only achieve these milestones, but also drive well past them. Imricor is a leading developer of innovative MRI-compatible medical devices for cardiac catheter ablation procedures, with its flagship product being the Vision-MR Ablation Catheter, which is approved for use in the European Union and the Kingdom of Saudi Arabia.

Imricor is well-positioned for continued growth and operational success in 2025 and beyond, with the funds from the capital raise enabling the company to accelerate its growth strategy, including expanding commercial operations, advancing research and development, and supporting regulatory efforts.